Market cap
$37 Mln
Recently Viewed
Clear AllMarket cap
$37 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1.3
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-32 Mln
ROE
-0.9 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-0.5
Debt to Equity
0.4
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
22,542,200
CFO
£-148.69 Mln
EBITDA
£-157.31 Mln
Net Profit
£-145.53 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
4D Pharma PLC ADR (LBPS)
| -69.7 | 0.0 | -56.1 | -81.9 | -- | -- | -- |
|
BSE Sensex*
| -8.7 | 2.7 | -5.2 | -2.4 | 8.6 | 9.8 | 11.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
4D Pharma PLC ADR (LBPS)
|
1.7 | 37.2 | 0.7 | -31.9 | -- | -105.8 | -- | 1.3 |
| 1.7 | 84.5 | 0.0 | -6.6 | -- | -- | -- | 14.1 | |
| 7.8 | 363.7 | 0.6 | -88.6 | -15,110.2 | -90.3 | -- | 5.8 |
4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004... for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, such as MRx1299 for solid tumors, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. In addition, the company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate MRx0518; strategic collaboration agreement with University of Texas MD Anderson for discovery and development of LBPs in oncology; and Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda, MRx0518 in patients with solid tumors, and to discover and develop LBPs for vaccines. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom. Read more
CEO & Exec. Director
Mr. Duncan Joseph Peyton
CEO & Exec. Director
Mr. Duncan Joseph Peyton
Headquarters
Leeds
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of 4D Pharma PLC ADR (LBPS) is $1.65 (NASDAQ) as of 28-Jul-2022 09:30 EDT. 4D Pharma PLC ADR (LBPS) has given a return of -81.89% in the last 1 years.
Since, TTM earnings of 4D Pharma PLC ADR (LBPS) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
|
2017
|
--
|
--
|
The 52-week high and low of 4D Pharma PLC ADR (LBPS) are Rs -- and Rs -- as of 27-Apr-2026.
4D Pharma PLC ADR (LBPS) has a market capitalisation of $ 37 Mln as on 28-Jul-2022. As per SEBI classification, it is a company.
Before investing in 4D Pharma PLC ADR (LBPS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.